A Phase 2a Open-Label Clin Trial Evaluating Efficacy and Safety of CPI-613 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML), and in Patients With Myelodysplastic Syndrome (MDS) Who Failed Hypomethylating Agents.

Trial Profile

A Phase 2a Open-Label Clin Trial Evaluating Efficacy and Safety of CPI-613 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML), and in Patients With Myelodysplastic Syndrome (MDS) Who Failed Hypomethylating Agents.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs CPI 613 (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Sponsors Rafael Pharmaceuticals
  • Most Recent Events

    • 05 Jun 2017 According to Cornerstone Pharmaceuticals media release, Cornerstone Pharmaceuticals changed name to Rafael Pharmaceuticals.
    • 27 Dec 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 03 Feb 2015 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018, as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top